| Cipla Limited - Mumbai. Related news |
Cipla rebounds 13% from 52-week low on heavy volumes
Posted on 11th October 2019 |
.jpg) |
Shares of Cipla gained 5 per cent to Rs 442, thus bouncing back 13 per cent from its early morning low on the BSE on Friday as, according to analysts, the USFDA's inspection of Goa facility found no repeat or data integrity (DI) observations, so there is no chance of import alerts at the plant. |
|
|
Cipla takes a knock on US FDA observations, overhang may continue
Posted on 30th September 2019 |
.jpg) |
Investors in Cipla Ltd’s stock have been seeing its value erode to a 52-week low from its 52-week high levels, with the stock tumbling 36% in the past one year. News that the US Food and Drug Administration has made some further observations on Cipla’s Goa plant has further compounded the company’s woes. So far today, the stock has shed 4.1% in trade. |
|
|
Cipla shareholders approve proposal to raise up to Rs 3,000 crore
Posted on 17th August 2019 |
.jpg) |
Drug major Cipla on Saturday said its shareholders have approved a proposal to raise up to Rs 3,000 crore through issuance of equity shares or other securities convertible into equity shares. Drug major Cipla on Saturday said its shareholders have approved a proposal to raise up to Rs 3,000 crore through issuance of equity shares or other securities convertible into equity shares. |
|
|
|
|
|
Cipla clocks ₹447 crore profit in Q1
Posted on 7th August 2019 |
.jpg) |
NEW DELHI: Drug major Cipla on Wednesday reported a marginal rise in consolidated net profit at ₹447.15 crore for the quarter ended June 30, 2019. The company had posted a net profit of ₹445.61 crore in the year-ago period, Cipla said in a filing to BSE. |
|
|
Cipla arm InvaGen Pharma gets USFDA nod for neuropathic pain management drug
Posted on 22nd July 2019 |
.jpg) |
Drug major Cipla Monday said its subsidiary InvaGen Pharmaceuticals has received final approval from the US health regulator for Pregabalin Capsules, indicated for management of neuropathic pain associated with certain illnesses. InvaGen has received approval from the the United States Food and Drug Administration (USFDA) for the drug in the strengths of 25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg and 300mg, Cipla said in a regulatory filing. |
|
|
Cipla Rating | Hold — Quarter results were ahead of expectations
Posted on 3rd June 2019 |
.jpg) |
Cipla reported Q4 results ahead of expectation led by gSensipar “at-risk” exclusivity launch. Ex of this, revenues were in line while margins were c100bps ahead of expectation. Management expects US business to grow in double digits in FY20 and base margins to improve though it did not quantify the level. Cipla trading at 20x FY21 PE, factors in the base business improvement. We retain Hold, noting the mixed execution over past 12m. |
|
|
Cipla to acquire US specialty drugmaker Avenue Therapeutics for Rs 15.6 bn
Posted on 13th November 2018 |
.jpg) |
Cipla has entered into an agreement to acquire US-based specialty pharma company Avenue Therapeutics Inc for $215 mn or around Rs 15.6 bn. This is in line with Cipla's strategy of building a specialty drugs pipeline in the US. Cipla's US subsidiary InvaGen Pharmaceuticals Inc will make the acquisition in two stages, the company said. |
|
|
Cipla gets USFDA nod for anti-viral eye infection drug for AIDS patients
Posted on 12th November 2018 |
.jpg) |
Drug major Cipla on Monday said it has received final approval from the US health regulator for Valganciclovir tablets used in the treatment of viral eye infection for AIDS patients. Valganciclovir is used in the treatment of cytomegalovirus infection (serious viral eye infection of the retina) for AIDS patients and for prevention of cytomegalovirus (CMV) disease after organ transplant. |
|
|
Cipla hits five-month low on weak outlook; down 12% in two days
Posted on 6th November 2018 |
.jpg) |
Shares of Cipla hit a five-month low of Rs 534, down 5% on Tuesday, extending its Monday’s 7% decline on the BSE, due to the weak outlook for the second half of the current fiscal (H2FY19). The pharmaceuticalmajor said there was pressure on the tender business, supply disruptions, commodity inflation and business impact from countries hit by sanctions. |
|
|
|
|
|
|
|
|
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
.jpg)
